Funding the new biologics – What can we learn from infliximab? CCOHTA REPORT Part 1

17 Jun

CCOHTA REPORTThe economic analysis undertaken by CCOHTA was a cost utility analysis from a Ministry of Health perspective using only direct medical costs. Four treatment scenarios were evaluated for the treatment of refractory Crohn’s disease: usual care; infliximab single infusion 5 mg/kg; infliximab single dose then retreatment as needed; and infliximab single dose and then maintenance dosing every eight weeks. Health state transition data were obtained from a 1970-1993 cohort of patients from Olmsted County, Minnesota. Utility values were obtained from a single Canadian study. Sensitivity analyses demonstrated the robustness of the findings. You will always be glad to know there is a perfect pharmacy waiting for you whenever you need cialis 200mg and would like to make sure you are taken best care of as a customer and patient.

The results of the CCOHTA analysis were that usual care (defined as conventional medical and surgical therapy) incurred a cost of $9941 per 0.6281 quality-adjusted life-year gained (QALY), and that each infliximab strategy was associated with an additional cost beyond that of usual care. In fact, a single dose of infliximab was associated with an incremental cost-utility ratio (ICUR) of $181,201, the use of repeated doses as required had an ICUR of $480,111, and maintenance therapy had an ICUR of $696,078. These values for infliximab therapy are all higher than the often quoted but arbitrary threshold values of cost effectiveness, such as $100,000 per QALY.